New ion channel hit identification agreement with Almirall
In September, Evotec announced a collaboration with
to identify small molecule modulators of an ion channel target, selected by Almirall, involved in respiratory diseases. Evotec will apply its in-depth electrophysiology and ion channel pharmacology expertise, as well as its state-of-the-art screening platform, for the identification and validation of novel modulators of the selected ion channel.
Fragment-based drug discovery alliance with Shionogi (after period-end)
In October, Evotec announced a multiple target drug discovery collaboration with
Shionogi & Co Ltd.
to identify small molecule modulators of various protein-protein interaction targets selected by Shionogi. Evotec will apply its proprietary and integrated fragment-based drug discovery platform, EVOlution(TM) to the programme to support Shionogi in finding novel treatments for inflammation and infectious diseases.
Pain alliance with Apeiron Biologics (after period-end)
Also in October, Evotec entered into a collaboration with
to identify small molecule modulators of DREAM (Downstream Regulatory Element Antagonistic Modulator), a novel target involved in various pain mechanisms. In a first instance, Evotec will apply its expertise in cellular assay development with opportunities for the project to rapidly move into hit identification and beyond. Further projects will be evaluated to potentially expand this collaboration in due course.
Milestone achievement with Boehringer Ingelheim
During the second quarter of 2010 strong progress was made in Evotec's discovery collaboration with
, with the first compound of this strategic alliance advancing into clinical trials. In July, a third milestone for 2010 in the amount of € 2.5 m was achieved for the progression of a candidate into pre-clinical studies. In total, Evotec has now achieved 10 milestones within this collaboration that was initiated in 2004.
Good progress in many discovery alliances (e.g. Vifor, Genentech); strong capacity utilisation
During the third quarter of 2010, the
collaboration was expanded to include a back-up programme to the current one and new screening projects were initiated with five partners. The
collaboration was expanded in July, and Evotec commenced work on three collaborations out of its operations in Thane, India.
3. STATUS OF CLINICAL AND PRECLINICAL PROGRAMMES AND PARTNERING OF ASSETS
Proprietary research programmes advancing; product development partnerships on track; new license agreement for EVT 201 for Chinese market (after period-end)
In addition to its continuous investment in the development of proprietary platform technologies for kick-starting discovery alliances Evotec is focused on obtaining value on a few carefully selected core assets. The Company is progressing those assets towards their optimal data points for partnering. To reduce Evotec's risk profile and limit its R&D expenses the Company is seeking strategic product development alliances to further advance these developments such as in the case of the partnership with Roche who fully fund the further development of EVT 100 compound family. The Company's early proprietary discovery programmes and high value development partnerships are all on track.